Special Issues
Detecting impurities in any chemical reaction is becoming increasingly important to detect those present at low levels (for example, 0.5%).
Detecting impurities in any chemical reaction is becoming increasingly important to detect those present at low levels (for example, 0.5%). Common methods of assessing purity include chromatography with a detector, such as an ultraviolet (UV) light detector, or an evaporative light scattering detector (ELSD). However, these detectors do not give any information about the molecular weight or structure of the impurities detected and thus make identification difficult.
A complementary detector, which can be used with a chromatograph, is the mass spectrometer (MS). Traditional MS systems available are too bulky, expensive to purchase and run, and power hungry for use in every laboratory. These limitations have lead to compromises in the choice of chromatography detectors that can be used in synthetic laboratories.
The Microsaic 4000 MiD® gives the chemist the ability to have a simple-to-use, low cost mass detector at the bench. The system is portable and modular so it can be easily integrated into a wide range of bench-top applications.
Here we report on how the Microsaic 4000 MiD® can be used as an HPLC detector to identify the presence of impurities that would otherwise be lost using popular detection methods.
Methods
Table I show the HPLC–MS conditions used for the impurity characterization.
Test samples were prepared, with the major component at 1 mg/mL and the minor one at 5 µg/mL (0.5% w/w). Two samples were prepared. Test sample A was made up by mixing Verapamil at 1 mg/mL and Bromopride at 5 µg/mL (0.5% w/w). Test sample B was Cortisone (1 mg/mL) and Verapamil (5 µg/mL–0.5% w/w).
Results and Discussion
Well Resolved Impurities
Test sample A contains two well resolved compounds, Bromopride and Verapamil, with the minor component eluting first. Both compounds are visible in the total ion chromatogram (TIC) shown in Figure 1. The mass spectra of the two chromatographic peaks confirmed the presence of bromopride and verapamil with m/z 344.4 and m/z 455.4, respectively.
Figure 1: Total ion chromatogram for test sample A.
Co-Eluting Impurities
Test sample B is an example of two compounds that coelute and could not be distinguished by UV only. Figure 2 shows the TIC and UV data of the cortisone–verapamil test mix. As expected, this shows a single major UV and TIC peak. When analyzing the TIC, mass spectra data are dominated by the cortisone ion, but the one from the tail of the peak shows an ion corresponding to verapamil.
Figure 2: Combined total ion and UV chromatograms of test sample B.
Conclusions
The Microsaic 4000 MiD® coupled to a HPLC enabled the identification of unknown impurities down to the low level of 0.5% (w/w) in full scanning mode. In the case of coelution on the HPLC system, the 4000 MiD® could help to identify an impurity where the UV data would provide misleading results.
Microsaic Systems plc
GMS House, Boundary Road, Woking, Surrey, UK
2024 EAS Awardees Showcase Innovative Research in Analytical Science
November 20th 2024Scientists from the Massachusetts Institute of Technology, the University of Washington, and other leading institutions took the stage at the Eastern Analytical Symposium to accept awards and share insights into their research.
Inside the Laboratory: The Richardson Group at the University of South Carolina
November 20th 2024In this edition of “Inside the Laboratory,” Susan Richardson of the University of South Carolina discusses her laboratory’s work with using electron ionization and chemical ionization with gas chromatography–mass spectrometry (GC–MS) to detect DBPs in complex environmental matrices, and how her work advances environmental analysis.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
Infographic: Be confidently audit ready, at any time and reduce failures in pharma QC testing
November 20th 2024Discover how you can simplify the audit preparation process with data integrity dashboards that provide transparency to key actions, and seamlessly track long-term trends and patterns, helping to prevent system suitability failures before they occur with waters_connect Data Intelligence software.
Critical Role of Oligonucleotides in Drug Development Highlighted at EAS Session
November 19th 2024A Monday session at the Eastern Analytical Symposium, sponsored by the Chinese American Chromatography Association, explored key challenges and solutions for achieving more sensitive oligonucleotide analysis.